



RNS Number : 6872B

Integrated Diagnostics Holdings PLC

27 August 2024

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

### Integrated Diagnostics Holdings plc

#### EGX Delisting - Share buyback under EGX's special operations market (OPR)

27 August 2024

Integrated Diagnostics Holdings plc ("IDH" or the "Company") refers to:

- (i) the shareholder resolutions passed at the Company's Extraordinary General Meetings held on 12 June 2024 and 18 July 2024 approving, amongst other things, the voluntary delisting (the "EGX Delisting") of the Company's ordinary shares (the "Shares") from the Egyptian Exchange (the "EGX") and the Company's repurchase of Shares from shareholders who hold Shares traded on the EGX held by Misr for Central Clearing, Depository and Custody ("MCDR") ("EGX Shares", and such shareholders, "EGX Shareholders") if so required by such EGX Shareholders during the relevant period; and
- (ii) the Company's announcement on 13 August 2024 in relation to the timeline under the EGX's special operations market (OPR).

Further to the closing of the tender period under the EGX's special operations market (OPR) on 22 August 2024, the Company has, on 26 August 2024, through EFG-Hermes International Securities Brokerage as its broker, initiated the buyback of all EGX Shares validly tendered into the special operations market (OPR), as follows:

Trading venue:	EGX
Tender period under the special operations market (OPR):	18 August 2024 to 22 August 2024
Date of buyback:	26 August 2024

Expected settlement date of buyback on the EGX:	28 August 2024
Number of EGX Shares purchased:	18,673,728
Purchase price per EGX Share:	20 Egyptian pounds

The Company intends to hold all 18,673,728 EGX Shares purchased by the Company (the "**Repurchased Shares**") as treasury shares. Following the settlement of the Repurchased Shares on the EGX, the Company will initiate the process to remove the Repurchased Shares from MCDR and for them to be held in the name of the Company as treasury shares (the "**Removal Process**"). The Removal Process is expected to complete on or about 2 September 2024.

Following the completion of the Removal Process, it is expected that:

- (a) the Company will hold 18,673,728 Shares as treasury shares (i.e. the Company does not currently hold any Shares in treasury); and
- (b) the Company's issued share capital will comprise a total of 581,326,272 Shares excluding the Shares held in treasury, compared to a total of 600,000,000 Shares which are currently in issue.

The Company will release a further announcement once the Removal Process has been completed.

Shareholders should note that, following the settlement of the buyback on the EGX and the subsequent decision of the EGX's Listing Committee (if and when made) to delist the Company's Shares and remove the same from its database, the remaining EGX Shares which were not validly tendered into the special operations market (OPR) and repurchased by the Company will no longer be capable of being traded on the EGX and will, subject to all applicable terms and conditions, and all necessary steps having been taken, be capable of being traded on the main market for listed securities of the London Stock Exchange, which will become the sole listing venue of the Company.

For further information please contact:

**Integrated Diagnostics Holdings plc**

**Tarek Yehia**

Investor Relations Director

T: +20 (0)2 3332 1126 | M: +20 10 6882 6678 | [tarek.yehia@idhcorp.com](mailto:tarek.yehia@idhcorp.com)

**Company Secretary**

**Company Matters**

[IDHLondon@linkgroup.co.uk](mailto:IDHLondon@linkgroup.co.uk)

-Ends-

**About Integrated Diagnostics Holdings (IDH)**

IDH is a leading diagnostics services provider in the Middle East and Africa offering a broad range of clinical pathology and radiology tests to patients in Egypt, Jordan, Nigeria, Sudan and Saudi Arabia. The Group's core brands include Al Borg, Al Borg Scan and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Echo-Lab (Nigeria), Ultralab and Al Mokhtabar in Sudan (both in Sudan), and Biolab KSA (Saudi Arabia). With over 40 years of experience, a long track record for quality and safety has earned the Company a trusted reputation, as well as internationally recognised accreditation. The Company's portfolio of over 3,000 diagnostics tests. From its base of 601 branches as of 31 December 2023, IDH served over 100 million patients and performed more than 36.1 million tests in 2023. IDH will continue to add laboratories through its Spoke and Spike business model that provides a scalable platform for efficient expansion. Beyond organic growth, the Group targets expansion in appealing markets, including acquisitions in the Middle Eastern, African, and East Asian markets where its model is well-suited to capitalise on similar healthcare and consumer trends and capture a significant share of fragmented markets. IDH is a Jersey-registered entity whose Shares (i) are admitted to the equity (transition) category (previously, the standard listing segment) of the Official List of the UK Financial Conduct Authority and admitted to trading on the main market for listed securities of the London Stock Exchange since May 2015 (IDHC), and (ii) until the decision of the EGX (if and when made) to delist the Company's Shares and remove them from its database following completion of the Removal Process outlined above, have a secondary listing on the Euronext Exchange (ticker: IDHC.CA).

Learn more at [idhcorp.com](https://idhcorp.com).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

POSEAKPKASELEFA